Enveric Biosciences Inc. (ENVB)
NASDAQ: ENVBHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ENVB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.80M
- EPS (TTM)
- -$13.01
- Dividend yield
- None
- 52-week range
- 1.17 – 13.25
- Day range
- 1.46 – 1.53
- Volume / Avg
- 64.87K / 102.84K
- Beta
- —
- Shares outstanding
- 4.48M
52-week range
ENVB stock today
Enveric Biosciences (ENVB) closed at $1.52 on Oct 8, up 1.67% (+$0.025), versus the S&P 500's 0.47% decline. Shares are 88.5% below their 52-week high of $13.25 and 29.9% above the 52-week low of $1.17, near the bottom of the past year's range. Enveric Biosciences has posted a net loss over the last twelve months (EPS of -$13.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Enveric Biosciences
Company profileEnveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Joseph Edward Tucker Ph.D.
- Headquarters
- Cambridge, MA
- Employees
- 5
- Website
- enveric.com
Enveric Biosciences peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LEXXLexaria Bioscience Corp. | 3.20 | -8.57% | $6.74M | vs ENVB |
| NRSNNeuroSense Therapeutics Ltd. | 3.58 | -6.28% | $6.79M | vs ENVB |
| XCURExicure Inc. | 1.00 | -1.96% | $6.55M | vs ENVB |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs ENVB |
| ALZNAlzamend Neuro Inc. | 1.34 | -2.19% | $6.47M | vs ENVB |
| ACXPAcurx Pharmaceuticals Inc. | 1.25 | -3.85% | $6.95M | vs ENVB |
| APREAprea Therapeutics Inc. | 0.5582 | -7.74% | $7.03M | vs ENVB |
| BOLTBolt Biotherapeutics Inc. | 3.65 | +1.39% | $7.03M | vs ENVB |
Indexes, lists and sector
Appears in lists
Enveric Biosciences stock FAQ
What is Enveric Biosciences's stock price today?
ENVB last traded at $1.52 as of Oct 8, 4:00 PM EDT, up 1.67% on the day. Prices are delayed at least 15 minutes.
Who is Enveric Biosciences's CEO?
Dr. Joseph Edward Tucker Ph.D. is the chief executive officer of Enveric Biosciences Inc., which has about 5 employees.
What is the ENVB 52-week high?
The 52-week high for ENVB is $13.25 and the 52-week low is $1.17. The stock is currently 88.5% below its high.